The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 123 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] Ness-Abramof, 2002, Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese., Obes Res sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] Smith, 1996, Localization of 11β-hydroxysteroid dehydrogenase type II in human epithelial tissues., J Clin Endocrinol Metab source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] Pecori Giraldi, 2007, Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series., J Clin Endocrinol Metab source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] Batista, 2007, Diagnostic tests for children who are referred for the investigation of Cushing syndrome, Pediatrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,401–1,500 of 2,716
Dexamethasone suppression for 18F-FDG PET/CT to localize ACTH-secreting pituitary tumors
Kim, K., Kim, D. K., Moon, J. H., Kim, E. H., Kim, S. H., Ku, C. R., & Lee, E. J. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00600-8 · Cited by 8
“A serum cortisol level suppressed by > 50% of the original level after 6 hourly administrations of 2 mg of DEX for 48 h was defined as suppression on the HD DST [27].”
MethodMansour, N., Brüdgam, D., Dischinger, U., Kürzinger, L., Adolf, C., Walter, R., Öcal, O., Schmidt, V. F., Rudolph, J., Ricke, J., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15013 · Cited by 9
“25,26 The lateralization index (LI) is defined as the aldosterone to cortisol ratio (ACR) on the dominant side with excess aldosterone secretion over ACR on the nondominant side.”
BackgroundPaopongpaiboon, P., Santisitthanon, P., Houngngam, N., Snabboon, T., & Boonchaya‐anant, P. (2024) · Clinical Endocrinology · doi:10.1111/cen.15020 · Cited by 6
Biochemical Control in Cushing's Syndrome: Outcomes of the Treatment in a Large Single Center Cohort
Ritzel, K., Fazel, J., August, L., Fedtke, V., Nowak, E., Vogel, F., Braun, L., Zopp, S., Then, C., Kunzel, H. E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae337 · Cited by 7
Exploring obesity-related endocrine disorders beyond diabetes: a narrative review
Meligi, A. A. H. E., Ahmed, R. M., Shaltout, I., & Soliman, A. R. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00358-w · Cited by 9
“Screening for Cushing’s syndrome (CS) is warranted in resistant hypertension or uncontrolled hyperglycemia despite intensive therapy. particularly in young patients [31].”
BackgroundWho and how to screen for endogenous hypercortisolism in adrenal and pituitary incidentaloma
Coscia, K., Verrienti, M., Dalmazi, G. D., & Zatelli, M. C. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02456-6 · Cited by 6
“Therefore, a combination of multiple tests should be performed to confirm the diagnosis of CS. ACTH levels need to be evaluated to determine the cause of CS, as adrenal tumors lead to ACTH-independent CS with suppressed/ low ACTH levels [ 46].”
InfluentialLee, B., Chang, C., Kang, V. J.-W., Huang, J.-Z., Lin, Y., Chang, Y., Tsai, C.-H., Chen, Z.-W., Liao, C.-W., Pan, C.-T., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01935-w · Cited by 6
“A tentative diagnosis of ACS was made if the PCC was >1.8 μ g/dL after the 1 mg DST [17, 18].”
InfluentialAhmed, A. S., Furqan, S., & Islam, N. (2012) · BMJ Case Reports · doi:10.1136/bcr.03.2012.6025 · Cited by 6
Cyclical Cushing's: how best to catch the ups and downs
Humayun, M. A., Hart, T., & Richardson, T. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-218451 · Cited by 6
Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!
Fleseriu, M. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa109 · Cited by 6
“The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline.”
BackgroundMethodInfluentialIatrogenic Cushing’S Syndrome as a Consequence of Nasal Use of Betamethasone Spray During Pregnancy
Scutelnicu, A. M., Panaitescu, A. M., Ciobanu, A.-M., Gică, N., Botezatu, R., Peltecu, G. C., & Gheorghiu, M. L. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.511 · Cited by 6
“The current guidelines recommend several tests to be used as firstline for the diagnosis of CS: late night salivary cortisol, 24 hours UFC and the overnight 1mg or 2mg/48 hours dexamethasone suppression tests; however, the normal values are not well-validated for pregnancy, therefore diagnosing CS in pregnancy is diff…”
MethodBleier, J., Pickovsky, J., Apter, S., Fishman, B., Dotan, Z., Tirosh, A., & Shlomai, G. (2021) · Clinical Endocrinology · doi:10.1111/cen.14651 · Cited by 9
“The 1‐mg DST was performed as outlined in the Endocrine Society 2008 guidelines for the diagnosis of Cushing's syndrome.(28) Briefly, prescriptions for 1mg of dexamethasone were issued, and patients were instructed to self‐administer the medication at 11:00 PM and perform blood tests at 8:00 AM the following morning.”
MethodMichailidou, M., Aggeletopoulou, I., Kouskoura, M. G., Zisimopoulos, K., Tsounis, E. P., Karaivazoglou, K., Tourkochristou, E., Mandellou, M., Διαμαντοπούλου, Γ., Κούτρας, Ν., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03055-2 · Cited by 6
Gupta, R., Walia, R., Ahuja, C. K., Dutta, A., Bhadada, S. K., Bhansali, A. K., Chhabra, R., Singh, A., & Dhandapani, S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.013 · Cited by 6
The Interaction of Obesity and Reproductive Function in Adolescents
Elliott, V., Waldrop, S., Wiromrat, P., Carreau, A., & Cree‐Green, M. (2022) · Seminars in Reproductive Medicine · doi:10.1055/s-0042-1744495 · Cited by 8
Mutational landscape of non-functional adrenocortical adenomas
Wu, L., Xie, J., Qi, Y., Su, T., Jiang, L., Zhou, W., Jiang, Y., Zhang, C., Zhong, X., Cao, Y., et al. (2022) · Endocrine Related Cancer · doi:10.1530/erc-21-0410 · Cited by 7
Cortisol as an Independent Predictor of Unfavorable Outcomes in Hospitalized COVID-19 Patients
Świątkowska−Stodulska, R., Berlińska, A., & Puchalska-Reglińska, E. (2022) · Biomedicines · doi:10.3390/biomedicines10071527 · Cited by 9
Association of Acne Tarda with Endocrinological Disorders
Makrantonaki, E., & Zouboulis, C. C. (2022) · Dermato · doi:10.3390/dermato2040010 · Cited by 7
Adrenal Liposarcoma: A Novel Presentation of Multiple Endocrine Neoplasia Type 1
Duro, T., & Gonzales, K. L. (2022) · AACE Clinical Case Reports · doi:10.1016/j.aace.2022.11.003 · Cited by 6
“6 mg/dL); and (10) 24-hour urine calcium level, 482 mg/24 hours (42-353 mg/24 hours).”
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion
Puglisi, S., Basile, V., Sperone, P., & Terzolo, M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09769-y · Cited by 7
“Although the preservation of the cortisol circadian rhythm in physiological pregnancy suggested the use of the midnight salivary cortisol for the diagnosis of hypercortisolism, the 2008 Endocrine Society guidelines did not recommend it, due to the lack of specific diagnostic thresholds in this subset of patients [20].”
BackgroundRecurrent Cushing Disease: An Extensive Review on Pros and Cons of Different Therapeutic Approaches
Sabahi, M., Ghasemi, P., Maroufi, S. F., Shahbazi, T., Yousefi, O., Shahtaheri, S. A., Bin-Alamer, O., Dabecco, R. M., Velasquez, N., Arce, K. M., et al. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.01.108 · Cited by 8
Asuzu, D. T., Bhatt, S., Nwokoye, D., Hayes, C. P., Cortes, M. X., McGlotten, R., Keil, M. F., Tatsi, C., Nieman, L. K., & Chittiboina, P. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad025 · Cited by 6
Self-citationHuckhagel, T., Atlihan, G., Länger, F. P., Flitsch, J., & Rotermund, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30070-8 · Cited by 6
Canat, M. M., Turkkan, C. Y., Erhan, H., Öztürk, F. Y., & Altuntaş, Y. (2023) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2023.14306 · Cited by 9
“[2] The diagnosis was confirmed by pathological evaluation after pituitary surgery.”
BackgroundMu, D., Fang, J., Yu, S., Ma, Y., Cheng, J., Hu, Y., Song, A., Zhao, F., Zhang, Q., Qi, Z., et al. (2023) · Annals of Laboratory Medicine · doi:10.3343/alm.2024.44.1.29 · Cited by 7
“CS was diagnosed according to the Endocrine Society guidelines [3] based on symptoms and abnormal circadian rhythms or increased cortisol secretion.”
The patient’s sex determines the hemodynamic profile in patients with Cushing disease
Jurek, A., Krzesiński, P., Uziębło‐Życzkowska, B., Witek, P., Zieliński, G., Kazimierczak, A., Wierzbowski, R., Banak, M., & Gielerak, G. G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1270455 · Cited by 6
Diverse presentations of Cushing's syndrome during pregnancy – A case series
Stoinis, N., Creeper, K. J., Phillips, J., Graham, D., & Lim, E. M. (2024) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13793 · Cited by 6
“8 Consequently it is important that 24-h UFC levels are compared with trimester-specific reference ranges (where available).”
Corrales, E. P., Cancela, A. A., Baonza, G., et al. (2024) · Acta Neurochirurgica · doi:10.1007/s00701-024-06107-w · Cited by 6
“On the other hand, the diagnosis and cure criteria for functioning pituitary tumors such as prolactinoma, Cushing disease and acromegaly were established based on the criteria of the clinical guidelines [12, 35, 44].”
Whole blood transcriptomic signature of Cushing's syndrome
Birtolo, M. F., Armignacco, R., Benanteur, N., Baussart, B., Villa, C., Murat, D. D., Guignat, L., Groussin, L., Libé, R., Zennaro, M., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae083 · Cited by 8
Syndrome de Cushing : quand y penser ? Comment l’affirmer ?
Guignat, L., & Bertherat, J. Y. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.02.005 · Cited by 6
Different levels of various glucocorticoid-regulated genes in corticotroph adenomas
Evang, J. A., Bollerslev, J., Casar‐Borota, O., Lekva, T., Ramm‐Pettersen, J., & Berg, J. P. (2013) · Endocrine · doi:10.1007/s12020-012-9871-0 · Cited by 7
Henry, R. K., Keil, M. F., Stratakis, C. A., & Fechner, P. Y. (2010) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2010.101 · Cited by 6
Moloney, K. J., Mercado, J. U., Ludlam, W. H., & Mayberg, M. R. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.49 · Cited by 7
Ривгатовна, Ш. З., Великанова, Л. И., Vorohobina, N. V., Lisitsyn, A. A., Кухианидзе, Е. А., Геннадьевна, С. Е., Povarov, V. G., & Talor, N. F. (2015) · Problems of Endocrinology · doi:10.14341/probl20156144-8 · Cited by 6
“Определение экскреции свободного кортизола с мочой (CКМ), свободного кортизола в слюне в 23 ч (СКС), уровней кортизола (К) и адренокортикотропного гормона (АКТГ) в плазме в ходе пробы с дексаметазоном являются стандартными тестами, используемыми в диагностике СИК [5—8].”
Serratia marcescens osteomyelitis in Cushing's disease
Martins, H., Raposo, A., Baptista, I., et al. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-212872 · Cited by 6
Factors predicting the outcomes of removal of corticotropinom in Cushing's disease
Marova, E. I., Kolesnikova, G. S., Arapova, S., et al. (2016) · Endocrine Surgery · doi:10.14341/serg2016420-30 · Cited by 6
“Может также встречаться гиперплазия кортикотрофов гипофиза с повышенной секрецией адренокортикотропного гормона (АКТГ) [1, 2].”
Nankova, A., Yaneva, M., Elenkova, A. P., Tcharaktchiev, D., Marinov, M., Hadzhiyanev, A., Sechanov, T., Gantchev, G., Todorov, G., Кirilov, G., et al. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0580-0460 · Cited by 6
Mojtahedzadeh, M., Shayesteh, N., Haykani, M., Tran, J., Mangubat, M., Shahinian, H. K., Nachnani, R., Zopey, M., Saidian, J., Thomas, A., et al. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0603-3868 · Cited by 6
“Patients suspected of Cushing’s syndrome should be screened with other tests such as nighttime serum or salivary cortisol measurements or UFC, as measured by chromatography, high-performance liquid chromatography (HPLC) or mass spectrometry with two different positive tests indicative of Cushing’s syndrome as suggeste…”
Nagai, Y., Mukai, K., Otsuki, M., Kimura, T., Kozawa, J., Nishizawa, H., Maeda, N., Matsuoka, T., Iwahashi, H., Imagawa, A., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1585-18 · Cited by 7
“First, depression and other psychiatric disorders, alcoholism, morbid obesity, and diabetes mellitus, which induce the activation of the HPA axis or physiological hypercortisolism, can cause false-positive low-dose DST results (17).”
BackgroundAndere spezifische Diabetesformen und exokrine Pankreasinsuffizienz (Update 2019)
Kaser, S., Winhofer-Stöckl, Y., Kazemi-Shirazi, L., Hofer, S. E., Brath, H., Sourij, H., Vila, G., Abrahamian, H., Riedl, M., Weitgasser, R., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1454-0 · Cited by 7
Pokrzywa, A., Ambroziak, U., Foroncewicz, B., Macech, M., Pączek, L., Florczak, M., Mucha, K., & Bednarczuk, T. (2019) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15091 · Cited by 8
Prasad, N., Jabbar, P. K., Chellamma, J., John, M., Haridasan, R. K., Anish, T. S., Gomez, R., Das, D., Sreenath, R., George, G. S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa269 · Cited by 7
Kumar, A., Kanwar, J., Bharti, N., Agrawal, V., Bhatia, E., & Yadav, S. C. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.12.011 · Cited by 6
Rosset, A., Greenman, Y., Osher, E., Stern, N., & Tordjman, K. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.02.012 · Cited by 7
Asha, H. S., Pai, R. B., Ramamoorthy, H., Sakhti, D., Manipadam, M. T., Kapoor, N., Paul, T. V., Jebasingh, F., Thomas, N., Abraham, D. T., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1402-0183 · Cited by 6
İsmailoğulları, S., Karaca, Z., Fırat, S. T., Ünlühızarcı, K., & Keleştimur, F. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1542-8816 · Cited by 7
“ACTH-secreting pituitary adenoma was diagnosed in the presence of normal or high plasma ACTH levels, appearent pituitary adenoma on MRI or was confirmed by bilateral inferior petrosal sinus sampling when pituitary MRI was inconclusive and treatment was based upon the etology of CS [25, 26].”
MethodDesmopressin Stimulation Test in a Pregnant Patient with Cushing's Disease
Parksook, W. W., Porntharukchareon, T., & Sunthornyothin, S. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2021.11.005 · Cited by 8
Hagiwara, R., Kageyama, K., Iwasaki, Y., Niioka, K., & Daimon, M. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0778 · Cited by 6
“CUSHING’S DISEASE is an endocrine disorder char‐ acterized by hypercortisolism, mainly caused by pituitary ACTH-producing adenomas [1, 2].”
BackgroundDoes concomitant prolactin measurement ıncrease the accuracy of ınferior petrosal sinus sampling?
Apaydin, T., Yasar, M., Baltacioglu, F., Haklar, G., & Gogas Yavuz, D. (2022) · Neuroradiology · doi:10.1007/s00234-021-02886-6 · Cited by 6
“1 3 in patients who have an adenoma smaller than 6 mm to rule out incidental adenomas or without a pituitary lesion on magnetic resonance imaging (MRI), and even in subjects with > 6 mm pituitary adenomas if corticotropin-releasing hormone (CRH) stimulation test or high dose dexamethasone suppression test is not avail…”
BackgroundThe Diagnosis of Cushing’s Syndrome
Nieman, L. K. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0011-0_4 · Cited by 9
Self-citationBeshyah, S., Almalki, M., Azzoug, S., Barake, M., Aldahmani, K. M., & Chihaoui, M. (2022) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0042-1755931 · Cited by 6
Etiologies of Cushing’s Syndrome
Newell-Price, J. D. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-449-4_2 · Cited by 6
Self-citationPeptic ulcer disease in endogenous hypercortisolism: myth or reality?
Hatipoğlu, E., Çağlar, A. S., Çağlar, E., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0608-8 · Cited by 6
Incidentally discovered pituitary masses: pituitary incidentalomas
Abdelmannan, D. K., & Aron, D. C. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.68 · Cited by 6
Prevalencia e incidencia de los principales trastornos endocrinos y metabólicos
Liberman, G. C. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70217-7 · Cited by 11
Telómeros, envejecimiento y síndrome de Cushing: ¿están relacionados?
Aulinas, A., Vives, A. S., Valassi, E., Mato, E., Crespo, I., Resmini, E., Roig, O., Bell, O. L., & Webb, S. M. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.10.002 · Cited by 8
Savage, M. O., & Storr, H. L. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0400 · Cited by 7
Self-citationLimitations of Basal Cortisol in the Diagnosis of Cushing Syndrome
Barros, A. P. T., Lamback, E. B., Coelho, M. C. A., & Neto, L. V. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0336 · Cited by 8
“Biochemical hypercortisolism must be confirmed before any attempt at differential diagnosis (3).”
BackgroundInhibin A as a tumor marker for primary bilateral macronodular adrenal hyperplasia
Wurth, R., Kamilaris, C. D. C., Nilubol, N., Sadowski, S. M., Berthon, A. S., Quezado, M., Faucz, F. R., Stratakis, C. A., & Hannah‐Shmouni, F. (2020) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-20-0006 · Cited by 7
Diagnosis and Treatment of Cushing’s Disease in Children
Savage, M. O., Dias, R. P., Chan, L. F., Afshar, F., Plowman, N. P., Matson, M. B., Grossman, A. B., & Storr, H. L. (2009) · Endocrine development · doi:10.1159/000262535 · Cited by 7
Self-citationAvaliação do eixo hipotálamo-hipófise adrenal no diagnóstico e na remissão da doença de Cushing
Costenaro, F., Rodrigues, T. D. C., Rollin, G., & Czepielewski, M. A. (2012) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302012000300002 · Cited by 10
“Importante ressaltar que é necessária a presença de dois ou mais testes alterados para realização do diagnóstico sindrômico (1,3).”
BackgroundInfluentialBiller, B. M. K., & Sheppard, M. C. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(09)00149-3 · Cited by 6
Self-citationSchwartz, G. L., & Krakoff, L. R. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.07.028 · Cited by 6
Cesana‐Nigro, N., Keshvari, S., Barclay, J. L., Sorbello, J., Upham, J. W., Benham, H., Anderson, S. T., Steiger, N., Prins, J. B., & Inder, W. J. (2019) · Clinical Endocrinology · doi:10.1111/cen.14108 · Cited by 6
“Osteoporosis n (%) 0 (0) 1 (5) 3 (16) 6 (46)”
Ronchi, C. L., Sbiera, S., Leich, E., Rosenwald, A., Allolio, B., & Faßnacht, M. (2013) · Endocrine Abstracts · doi:10.1530/endoabs.32.oc4.2 · Cited by 7
Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome
Barnes, R. B., Ehrmann, D. A., & Rosenfield, R. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00132-5 · Cited by 7
Bertholf, R. L., Jialal, I., & Winter, W. E. (2012) · Tietz Textbook of Clinical Chemistry and Molecular Diagnostics · doi:10.1016/b978-1-4160-6164-9.00054-8 · Cited by 5
Masri‐Iraqi, H., Rudman, Y., Shochat, T., Kushnir, S., Shimon, I., Fleseriu, M., & Akirov, A. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02535-2 · Cited by 7
Pivonello, C., Patalano, R., Negri, M., Treppiedi, D., Peverelli, E., Amatrudo, F., Provvisiero, D. P., Simeoli, C., Paola, N. D., Larocca, A., et al. (2025) · Endocrinology · doi:10.1210/endocr/bqaf107 · Cited by 4
Adrenal Incidentaloma: From Silent Diagnosis to Clinical Challenge
Mirică, A., Tilici, D.-M., Păun, D. L., Arnautu, A. M., Nimigean, V., & Paun, S. C. (2025) · Biomedicines · doi:10.3390/biomedicines13092298 · Cited by 8
“Confirmatory testing for overt cortisol excess may include late-night salivary cortisol, 24 h urinary free cortisol (UFC), or a 2-day low-dose dexamethasone suppression test, with positivity in at least two of three tests supporting the diagnosis of overt Cushing’s syndrome [2,26].”
Agha, A., Gunasekaran, S. D., Noor, E. M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186656 · Cited by 5
“This included weekly cabergoline or daily bromocriptine for prolactinomas; somatostatin receptor ligands and/or pegvisomant for acromegaly; and steroidogenesis inhibitors (e.g., ketoconazole and metyrapone) or pasireotide for Cushing’s disease [18,19].”
Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome
Tabarin, A., Bertherat, J. Y., Decoudier, B., Lasolle, H., Lefèbvre, H., Drui, D., Vaillant, C., Morera, J., Castinetti, F., Cristante, J., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf633 · Cited by 10
Vaduva, P., Violon, F., Chansavang, A., Hadjadj, D., Raverot, G., Espiard, S., Attia, A., Bouys, L., Thomeret, L., Kuhn, A. W., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf255 · Cited by 5
Martínez, W. A. R., Castaño, M. J. R., Calderón, S. C., Posada, N. A. D., Restrepo, J. G., Román-Gonzaléz, A., Henao, N. A., Castaño, P., Tobón-Ospina, C., Gómez, J. H. D., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261434078 · Cited by 5
“The diagnosis of CS required at least two abnormal first-line biochemical screening tests, following the Endocrine Society Clinical Practice Guideline 10 and updated international consensus recommendations.”
InfluentialZhang, W., Wang, Y., Wei, Z. C., Chang, G., Luo, Q., Abudusailamu, N., Nurula, M., Tao, S., Li, H., & Chen, Y. (2019) · Springer eBooks · doi:10.1007/978-981-15-0591-1_9 · Cited by 5
Adrenal hyperplasias in childhood: An update
Pitsava, G., & Stratakis, C. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.937793 · Cited by 6
“If ACTH levels are <5pg/mL, then ACTHindependent disease is suggested, while ACTH levels ≥29pg/ml have approximately 70% sensitivity in identifying ACTHdependent disease in children (35, 43).”
BackgroundMethodThe molecular genetics of adrenal cushing
Vaduva, P., & Bertherat, J. Y. (2024) · HORMONES · doi:10.1007/s42000-024-00608-0 · Cited by 5
“Endogenous Cushing’s syndrome is due in around 20% of cases to adrenal gland diseases, encompassing adenomas, carcinomas, and bilateral adrenal tumors [1, 2].”
Voltan, G., Mazzeo, P., Cannito, M., Pinelli, S., Barbot, M., Scaroni, C. M., Ceccato, F., & Camozzi, V. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf008 · Cited by 8
Han, M.-M., Cao, X.-M., Liu, Z., Zhang, Y., & Liu, Y. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i3.100580 · Cited by 5
SECONDARY (ENDOCRINE) HYPERTENSION: LECTURE
Yukina, M. Y., Troshina, E. A., Beltsevich, D. G., & Platonova, N. M. (2016) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2016-44-4-501-512 · Cited by 6
Co-Occurrence of Exogenous and Endogenous Cushing’s Syndromes—Dilemma in Diagnosis
Tong, C. V., & Rajoo, S. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/2986312 · Cited by 7
Durcan, E., Keskin, F. E., Özkaya, H. M., Şirolu, S., Şahin, S., Korkmaz, Ö. P., Gazioğlu, N., Tanrıöver, N., Çomunoğlu, N., Öz, B., et al. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1523-7216 · Cited by 5
Median 10 years follow-up of patients with covert Cushing’s syndrome: a case series
Najafipour, F., Bahrami, A., Niafar, M., et al. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-03046-3 · Cited by 5
“The most common cause of Cushing’s syndrome is exogenous Cushing’s syndrome, so, initially, exogenous Cushing’s should be excluded [3].”
BackgroundIncretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
Barbot, M., Mondin, A., Regazzo, D., Guarnotta, V., Basso, D., Giordano, C. S. D. S., Scaroni, C. M., & Ceccato, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095217 · Cited by 5
“CD diagnosis was established based on Endocrine Society Guidelines [16].”
MethodFarrell, G., Wang, S., Chapple, C., Kennedy, E., Gisselman, A. S., Sampath, K. K., Cook, C. E., & Tumilty, S. (2022) · Physical Therapy Reviews · doi:10.1080/10833196.2022.2096195 · Cited by 6
Hacıoğlu, A., Fırat, S. T., Caglar, A. S., Karaca, Z., Kalay, N., Taheri, S., Tanrıverdi, F., Selcuklu, A., Unluhizarci, K., & Keleştimur, F. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02183-4 · Cited by 6
“The diagnosis of CS was based on the criteria established by the Endocrine Society [21].”
Tarçın, G., Çatlı, G., Çetinkaya, S. Ç., Eren, E., Kardelen, A. D., Akıncı, A., Böber, E., Kara, C., Yıldırım, R., Er, E., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14980 · Cited by 10
“10 Although the data regarding the growth velocity of the patients before admission was not available in this study, the significant improvement in their height SDS after treatment indirectly indicates that the linear growth had been decelerated.”
BackgroundAl-Waeli, D. K., Alidrisi, H. A., & Mansour, A. A. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2023-0092 · Cited by 6
“However, ACTH has a short half‑ life and exhibits pulsatile secretion, which can lead to overlapping levels in healthy individuals [2, 5].”
BackgroundGüneş, M., Güneş, E., Kaya, M. İ., Küçükelyas, H. D., Barut, H., & Öner, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.002 · Cited by 7
Casteràs, A., Fidilio, E., Comas, M., Zabalegui, A., Flores, V., Giralt, M., Troyano, N. D., Ferrer, R., Vilallonga, R., Ciudin, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175146 · Cited by 8
“DST with overnight administration of 1 mg dexamethasone (23:00 h) is considered one of the diagnostic gold standard tests of autonomous cortisol secretion and is frequently used in clinical practice [27,28].”
BackgroundMethodGiordano, R., Parasiliti‐Caprino, M., Loli, P., & Giustina, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02450-y · Cited by 9
Impact of Female Sex and Mild Cortisol Secretion on Coagulation Profile in Adrenal Incidentalomas
Bonaventura, I., Minnetti, M., Ferrari, D., Hasenmajer, V., Tomaselli, A., Alcubierre, D. D., Lenzi, A., Pofi, R., & Isidori, A. M. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae215 · Cited by 5
Nebennierentumoren: Grundlagen der Diagnostik und operativen Therapie
Gonsior, A., Pfeiffer, H., Führer, D., LIATSIKOS, E. N., Schwalenberg, T., & Stolzenburg, J.-U. (2010) · Der Urologe · doi:10.1007/s00120-010-2296-6 · Cited by 5
Giordano, R., Berardelli, R., Karamouzis, I., D’Angelo, V., Picu, A., Zichi, C., Fussotto, B., Manzo, M. L., Mengozzi, G., Ghigo, E., et al. (2012) · Pituitary · doi:10.1007/s11102-012-0433-5 · Cited by 5
Bartz, S. K., Karaviti, L. P., Brandt, M. L., López, M. E., Masand, P. M., Devaraj, S., Hicks, J. M., Anderson, L. R., Lodish, M. B., Keil, M. F., et al. (2015) · International Journal of Pediatric Endocrinology · doi:10.1186/s13633-015-0014-2 · Cited by 6
“Treatment reverses, but may not completely normalize, many of the deleterious effects of hypercortisolism short term or long term [4].”
BackgroundAn Unusual Presentation of Pediatric Cushing Disease: Diabetic Ketoacidosis
Çatlı, G., Abacı, A., Tanrısever, O., Koçyiğit, C., Can, P.-R., & Dündar, B. N. (2015) · AACE Clinical Case Reports · doi:10.4158/ep14284.cr · Cited by 5
Asymmetric Dimethylarginine Levels and Atherosclerosis Markers in Cushing Syndrome
Özsürekçi, C., Aktürk, M., Özkan, Ç., Gülbahar, Ö., Altınova, A. E., Yalcin, M., Arslan, E., & Törüner, F. B. (2016) · Endocrine Practice · doi:10.4158/ep15990.or · Cited by 5
Lee, J.-M., Kim, M. K., Ko, S., Koh, J., Kim, B., Kim, S.-W., Kim, S., Kim, H. J., Ryu, O., Park, J., et al. (2017) · Korean Journal of Medicine · doi:10.3904/kjm.2017.92.1.4 · Cited by 5
“0 μg/dL (138 nmol/L)로 하면 특이도가 95% 이상이나 민감도가 떨어진다 [7,21,22,24,25].”
InfluentialBuonacera, A., Stancanelli, B., & Malatino, L. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0200-9 · Cited by 5
How Useful is Urinary-Free Cortisol in the Clinic?
Sheriff, N., & McCormack, A. I. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0311 · Cited by 7
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.